183 related articles for article (PubMed ID: 31323130)
1. Diaphragm involvement in immune checkpoint inhibitor-related myositis.
Sekiguchi K; Hashimoto R; Noda Y; Tachibana H; Otsuka Y; Chihara N; Shiraishi Y; Inoue T; Ueda T
Muscle Nerve; 2019 Oct; 60(4):E23-E25. PubMed ID: 31323130
[No Abstract] [Full Text] [Related]
2. [A case of myasthenia gravis and myositis induced by pembrolizumab].
Noda T; Kageyama H; Miura M; Tamura T; Ito H
Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
Haddox CL; Shenoy N; Shah KK; Kao JC; Jain S; Halfdanarson TR; Wijdicks EF; Goetz MP
Ann Oncol; 2017 Mar; 28(3):673-675. PubMed ID: 27993808
[No Abstract] [Full Text] [Related]
4. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
5. Myasthenia gravis and respiratory failure related to phrenic nerve lesion.
Valadas A; de Carvalho M
Muscle Nerve; 2008 Oct; 38(4):1340-1. PubMed ID: 18785183
[No Abstract] [Full Text] [Related]
6. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673
[TBL] [Abstract][Full Text] [Related]
7. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
[TBL] [Abstract][Full Text] [Related]
8. Electrophysiological monitoring in neurological respiratory insufficiency.
Zifko U; Young BG; Bolton CF
J Neurol Neurosurg Psychiatry; 1997 Mar; 62(3):299-300. PubMed ID: 9069502
[No Abstract] [Full Text] [Related]
9. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
10. A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab.
Takahashi S; Mukohara S; Hatachi S; Yamashita M; Kumagai S
Scand J Rheumatol; 2020 Nov; 49(6):509-511. PubMed ID: 32914675
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitors (ICIs)-related ocular myositis.
Garibaldi M; Calabrò F; Merlonghi G; Pugliese S; Ceccanti M; Cristiano L; Tartaglione T; Petrucci A
Neuromuscul Disord; 2020 May; 30(5):420-423. PubMed ID: 32387281
[TBL] [Abstract][Full Text] [Related]
12. Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings.
Imai R; Ono M; Nishimura N; Suzuki K; Komiyama N; Tamura T
J Thorac Oncol; 2019 Feb; 14(2):e36-e38. PubMed ID: 30391574
[No Abstract] [Full Text] [Related]
13. Myasthenia triggered by immune checkpoint inhibitors: New case and literature review.
Gonzalez NL; Puwanant A; Lu A; Marks SM; Živković SA
Neuromuscul Disord; 2017 Mar; 27(3):266-268. PubMed ID: 28109638
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
[TBL] [Abstract][Full Text] [Related]
15. Significance of phrenic nerve electrophysiological abnormalities in Guillain-Barré syndrome.
Durand MC; Prigent H; Sivadon-Tardy V; Orlikowski D; Caudie C; Devaux C; Clair B; Gaillard JL; Lofaso F; Raphael JC; Sharshar T
Neurology; 2005 Nov; 65(10):1646-9. PubMed ID: 16301497
[TBL] [Abstract][Full Text] [Related]
16. A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.
Stefanou MI; Komorowski L; Kade S; Bornemann A; Ziemann U; Synofzik M
BMC Neurol; 2016 Sep; 16(1):172. PubMed ID: 27623618
[TBL] [Abstract][Full Text] [Related]
17. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of phrenic nerve and diaphragm function with peripheral nerve stimulation and M-mode ultrasonography in potential pediatric phrenic nerve or diaphragm pacing candidates.
Skalsky AJ; Lesser DJ; McDonald CM
Phys Med Rehabil Clin N Am; 2015 Feb; 26(1):133-43. PubMed ID: 25479785
[TBL] [Abstract][Full Text] [Related]
19. Significance of phrenic nerve electrophysiological abnormalities in Guillain-Barré syndrome.
Bolton CF
Neurology; 2006 Jun; 66(12):1961; author reply 1961. PubMed ID: 16801681
[No Abstract] [Full Text] [Related]
20. Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy.
Onda A; Miyagawa S; Takahashi N; Gochi M; Takagi M; Nishino I; Suzuki S; Oishi C; Yaguchi H
Intern Med; 2019 Jun; 58(11):1635-1638. PubMed ID: 30713313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
